# US 2026/0216364 A1 · Antibody drug conjugate

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0216364 A1
- Document ID: US20260216364A1
- Status: Published application
- Kind: A1
- Application number: 19/640,639
- Filed: 2026-04-07
- Published: 2026-07-30
- Earliest claimed: 2020-08-13
- Assignees: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Nanjing Shunxin Pharmaceuticals Co., Ltd. of Chiatai Pharmaceutical Group
- Applicants: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Nanjing Shunxin Pharmaceuticals Co., Ltd. of Chiatai Pharmaceutical Group
- Inventors: Xiquan ZHANG; Tianxi CHEN; Weiwei FENG; Bing ZHANG; Xiaoqi TANG; Tongjie XU; Xiaojin WANG; Huace SHENG; Zhengping ZHANG; Hua WANG; Yong GAO
- Web page: https://patentgrep.com/patent/US20260216364A1

## CPC

- A61K 47/68037: {the drug being a camptothecin [CPT] or derivatives}
- A61K 47/6855: {the tumour determinant being from breast cancer cell}
- A61K 47/545: {Heterocyclic compounds (A61K47/558 takes precedence)}
- A61K 47/65: Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
- A61K 47/6803: {Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates}
- A61K 47/6879: {the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin}
- A61P 35/00: Antineoplastic agents
- C07B 59/008: {Peptides; Proteins}
- C07K 16/32: against translation products of oncogenes
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- C07K 2317/31: multispecific
- C07K 2317/41: Glycosylation, sialylation, or fucosylation
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided is an antibody drug conjugate, specifically comprising a therapeutic antibody moiety, an intermediate linker moiety and a cytotoxic drug moiety which are linked. The therapeutic antibody moiety is an antibody against an HER2 target. The cytotoxic drug moiety is a camptothecin topoisomerase I inhibitor. The cytotoxic drug moiety or the linker-cytotoxic drug moiety is modified by means of deuterium substitution. The antibody drug conjugate can be used for the prevention or treatment of cancers.

## Claims

### Claim at position 1

1-25. (canceled)

### Claim 26

An antibody-drug conjugate of general formula Ab-(L-U)n, or a pharmaceutically acceptable salt or a solvate thereof, wherein Ab represents an antibody moiety, L represents a linker moiety, U represents a cytotoxic drug moiety, and n is an integer or a decimal selected from the group consisting of 2 to 10,
wherein the antibody-drug conjugate has a structure of formula VII-1 below:
wherein the Ab represents an antibody moiety comprising a first antigen-binding fragment and a second antigen-binding fragment,
wherein the first antigen-binding fragment is an scFv and comprises a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2 and a light chain CDR3, the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 comprising amino acid sequences set forth in SEQ ID NOs: 43, 28 and 29, respectively, and the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprising amino acid sequences set forth in SEQ ID NOs: 30, 31 and 32, respectively,
the second antigen-binding fragment is an Fab and comprises a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2 and a light chain CDR3, the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 comprising amino acid sequences set forth in SEQ ID NOs: 45, 46 and 47, respectively, and the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprising amino acid sequences set forth in SEQ ID NOs: 48, 49 and 50, respectively.

### Claim 27 (depends on 26)

The antibody-drug conjugate, or the pharmaceutically acceptable salt or the solvate thereof according to claim 26, wherein n is an integer or a decimal selected from the group consisting of 3 to 8.

### Claim 28 (depends on 27)

The antibody-drug conjugate, or the pharmaceutically acceptable salt or the solvate thereof according to claim 27, wherein n is an integer or a decimal selected from the group consisting of 5 to 8.

### Claim 29 (depends on 26)

The antibody-drug conjugate, or the pharmaceutically acceptable salt or the solvate thereof according to claim 26, wherein the first antigen-binding fragment comprising a heavy chain variable region and a light chain variable region which comprise amino acid sequences having at least 80% identity to the amino acid sequences set forth in SEQ ID NOs: 41 and 42, respectively.

### Claim 30 (depends on 26)

The antibody-drug conjugate, or the pharmaceutically acceptable salt or the solvate thereof according to claim 26, wherein the first antigen-binding fragment comprises a heavy chain variable region and a light chain variable region comprising amino acid sequences set forth in SEQ ID NOs: 35 and 36, respectively, and
the second antigen-binding fragment comprises a heavy chain variable region and a light chain variable region comprising amino acid sequences set forth in SEQ ID NOs: 37 and 38, respectively.

### Claim 31 (depends on 26)

The antibody-drug conjugate, or the pharmaceutically acceptable salt or the solvate thereof according to claim 26, wherein the first antigen-binding fragment is monovalent and specifically binds to an ECD4 epitope of HER2 on an HER2-expressing cell, and
the second antigen-binding fragment is monovalent and specifically binds to an ECD2 epitope of HER2 on an HER2-expressing cell.

### Claim 32 (depends on 26)

The antibody-drug conjugate, or the pharmaceutically acceptable salt or the solvate thereof according to claim 26, wherein a VH and VL of the first antigen-binding fragment is arranged from N-terminus to C-terminus in the following order: VH-linker-VL.

### Claim 33 (depends on 26)

The antibody-drug conjugate, or the pharmaceutically acceptable salt or the solvate thereof according to claim 26, wherein the antibody moiety Ab comprises a human Fc operably linked to a first antigen-binding fragment and a second antigen-binding fragment.

### Claim 34 (depends on 33)

The antibody-drug conjugate, or the pharmaceutically acceptable salt or the solvate thereof according to claim 33, wherein the Fc is derived from IgG1 or IgG4.

### Claim 35 (depends on 33)

The antibody-drug conjugate, or the pharmaceutically acceptable salt or the solvate thereof according to claim 33, wherein the Fc is a dimeric Fc comprising a first Fc polypeptide and a second Fc polypeptide, the first antigen-binding fragment is operably linked to the first Fc polypeptide, and the second antigen-binding fragment is operably linked to the second Fc polypeptide.

### Claim 36 (depends on 35)

The antibody-drug conjugate, or the pharmaceutically acceptable salt or the solvate thereof according to claim 35, wherein the dimeric Fc has an H435R modification or/and a Y436F modification, which only occur in one Fc polypeptide rather than in the other Fc polypeptide.

### Claim 37 (depends on 35)

The antibody-drug conjugate, or the pharmaceutically acceptable salt or the solvate thereof according to claim 35, wherein the dimeric Fc has mutation sites of knob-into-hole.

### Claim 38 (depends on 26)

The antibody-drug conjugate, or the pharmaceutically acceptable salt or the solvate thereof according to claim 26, wherein the antibody moiety Ab is a bivalent bispecific antibody, comprising: a heavy chain comprising an amino acid sequence set forth in SEQ ID NO: 11, a heavy chain comprising an amino acid sequence set forth in SEQ ID NO: 13, and a light chain comprising an amino acid sequence set forth in SEQ ID NO: 15.

### Claim 39 (depends on 26)

A pharmaceutical composition comprising the antibody-drug conjugate, or the pharmaceutically acceptable salt or the solvate thereof of according to claim 26, and a pharmaceutically acceptable carrier.

### Claim 40 (depends on 26)

A method of treating cancer, comprising administering to a patient in need thereof a therapeutically effective amount of the antibody-drug conjugate, or the pharmaceutically acceptable salt or the solvate thereof according to claim 26.

### Claim 41 (depends on 40)

The method according to claim 40, wherein the cancer is HER2 positive cancer, HER2 negative cancer, cancer that shows HER2 expression as IHC2+ detected by immunohistochemical assay, breast cancer or triple-negative breast cancer.

### Claim 42 (depends on 39)

A method of treating cancer, comprising administering to a patient in need thereof a therapeutically effective amount of the pharmaceutical composition according to claim 39.

### Claim 43 (depends on 42)

The method according to claim 42, wherein the cancer is HER2 positive cancer, HER2 negative cancer, cancer that shows HER2 expression as IHC2+ detected by immunohistochemical assay, breast cancer or triple-negative breast cancer.
